It turned out that miR-877-3p which targeted the −320~–299 site of the p16 promoter could increase the expression of p16 in bladder cancer cells on both mRNA and protein levels, which was because of the direct binding between miR-877-3p and p16 promoter. This evidence concerns the gene CDKN2A and urinary bladder cancer.